The estimated Net Worth of Bryan Giraudo is at least 3.23 百万$ dollars as of 18 June 2024. Mr. Giraudo owns over 100,000 units of Gossamer Bio stock worth over 427,209$ and over the last 6 years he sold GOSS stock worth over 155,144$. In addition, he makes 2,647,280$ as Chief Financial Officer at Gossamer Bio.
Sign up
Mr. Giraudo GOSS stock SEC Form 4 insiders trading
Bryan has made over 15 trades of the Gossamer Bio stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 100,000 units of GOSS stock worth 59,000$ on 18 June 2024.
The largest trade he's ever made was buying 200,000 units of Gossamer Bio stock on 13 November 2023 worth over 112,000$. On average, Bryan trades about 14,770 units every 70 days since 2018. As of 18 June 2024 he still owns at least 480,010 units of Gossamer Bio stock.
You can see the complete history of Mr. Giraudo stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Bryan Giraudo biography
Bryan M. Giraudo serves as Chief Financial Officer of the Company. Prior to joining us, Mr. Giraudo was a Senior Managing Director at Leerink Partners (now known as SVB Leerink) from 2009 to April 2018, where he was responsible for their western North America and Asia Pacific biotechnology and medical technology banking practice. Before joining Leerink, Mr. Giraudo was a Managing Director in Merrill Lynch, Pierce, Fenner & Smith Incorporated’s Global Healthcare Investment Banking Group. He has been a member of the board of directors of Protagonist Therapeutics, Inc. since May 2018. Mr. Giraudo received his B.A. from Georgetown University.
What is the salary of Bryan Giraudo?
As the Chief Financial Officer of Gossamer Bio, the total compensation of Bryan Giraudo at Gossamer Bio is 2,647,280$. There are 1 executives at Gossamer Bio getting paid more, with Jakob Dupont having the highest compensation of 3,530,450$.
How old is Bryan Giraudo?
Bryan Giraudo is 44, he's been the Chief Financial Officer of Gossamer Bio since 2018. There are 16 older and no younger executives at Gossamer Bio. The oldest executive at Gossamer Bio, Inc. is Thomas Daniel, 66, who is the Independent Director.
What's Bryan Giraudo's mailing address?
Bryan's mailing address filed with the SEC is 3013, Science Park Road, Torrey Pines, San Diego, San Diego County, California, 92121, United States.
Insiders trading at Gossamer Bio
Over the last 6 years, insiders at Gossamer Bio have traded over 10,765,709$ worth of Gossamer Bio stock and bought 2,039,396 units worth 4,494,757$ . The most active insiders traders include Kristina Burow、Faheem Hasnain、Fund V, L.P.Omega Fund V Gp.... On average, Gossamer Bio executives and independent directors trade stock every 33 days with the average trade being worth of 40,853$. The most recent stock trade was executed by Richard Aranda on 24 June 2024, trading 1,908 units of GOSS stock currently worth 1,259$.
What does Gossamer Bio do?
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2, which is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma; in Phase II clinical trial to treat patients with chronic rhinosinusitis with and without nasal polyps; and in Phase 2 clinical trial in patients with chronic spontaneous urticarial. The company is also developing GB002, an orally inhaled, small molecule, platelet-derived growth factor receptor kinase inhibitor in Phase Ib clinical trial for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule in Phase Ib clinical trial for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; and GB1275, an oral, small molecule, CD11b modulator in Phase 1/2 clinical trial for the treatment of selected solid tumor types. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
What does Gossamer Bio's logo look like?
Complete history of Mr. Giraudo stock trades at Protagonist Therapeutics Inc、Gossamer Bio
Gossamer Bio executives and stock owners
Gossamer Bio executives and other stock owners filed with the SEC include:
-
Jakob Dupont,
Chief Medical Officer -
Bryan Giraudo,
Chief Financial Officer -
Luisa Salter-Cid,
Chief Scientific Officer -
Faheem Hasnain,
Chairman of the Board, President, Chief Executive Officer -
Christian Waage,
Executive Vice President, General Counsel -
Faheem Hasnain,
Co-Founder, CEO, Pres & Chairman -
Bryan Giraudo,
COO & CFO -
Christian Waage,
Exec. VP, Gen. Counsel & Sec. -
Dr. Luisa Salter-Cid Ph.D.,
Chief Scientific Officer -
Renee Gala,
Independent Director -
Russell Cox,
Independent Director -
Joshua Bilenker,
Independent Director -
Kristina Burow,
Independent Director -
Thomas Daniel,
Independent Director -
Caryn L. Peterson,
Exec. VP of Regulatory Affairs -
Dr. Richard Aranda M.D.,
Chief Medical Officer -
Dr. Laura L. Carter Ph.D.,
Chief Scientific Officer -
Mario Orlando,
VP of Commercial New Product Planning -
Dr. Robert F. Roscigno,
VP of Clinical Devel. -
Dr. Larry Zisman M.D.,
Sr. Director of Clinical Devel. -
Dr. Richard Aranda,
Sr. VP of Clinical Devel. -
Deanna Weber,
Sr. VP of HR -
Steven D Nathan,
Director -
Skye Drynan,
Director -
John D Quisel,
Director -
Caryn Peterson,
EVP, Regulatory Affairs -
Sheila Gujrathi,
President & CEO -
Fund V, L.P.Omega Fund V Gp...,
-
Otello Stampacchia,
Director -
Fund V, L.P.Omega Fund V Gp...,
-
Venture Partners Ix, Llcarc...,
-
Laura Carter,
Chief Scientific Officer -
Richard Aranda,
Chief Medical Officer -
Robert Paul Jr Smith,
Chief Commercial Officer